NCT02612077
Completed
Not Applicable
A Cohort Survey of Patients With Metastatic Colorectal Cancer Starting a Chemotherapy in Combination With Avastin®
ConditionsMetastatic Colorectal Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Observational Chemotherapy
- Conditions
- Metastatic Colorectal Cancer
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 765
- Primary Endpoint
- Progression-free Survival
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This is a longitudinal, multicenter, prospective, pharmacoepidemiological study to evaluate progression free survival (PFS) in a real-life setting in participants with metastatic colorectal cancer (mCRC) starting chemotherapy combined with bevacizumab.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Having colon or rectal metastatic adenocarcinoma, for which the physician decided during the inclusion visit to start a treatment with bevacizumab combined with a 1st, 2nd or 3rd line chemotherapy
- •Having received oral and written information about the survey and not objecting to having his/her data computerized
Exclusion Criteria
- •Participating in a clinical trial assessing an anticancer treatment
Arms & Interventions
Observational Chemotherapy/Bevacizumab
Observed patients receiving chemotherapy with concomitant bevacizumab
Intervention: Observational Chemotherapy
Observational Chemotherapy/Bevacizumab
Observed patients receiving chemotherapy with concomitant bevacizumab
Intervention: Concomitant Bevacizumab
Outcomes
Primary Outcomes
Progression-free Survival
Time Frame: within 36 months
Kaplan Meier estimates of median progression-free survival according to the metastatic line of treatment, for a median follow-up of 18, 15 and 13 months, respectively
Secondary Outcomes
- Overall Survival(Up to 36 months)
- Quality of Life - Global Health Status(Baseline, 6 and 12 months)
Similar Trials
Completed
Not Applicable
Epidemiology and Management of Metastatic Breast CancerBreast Cancer Nos Metastatic RecurrentNCT01711502AstraZeneca128
Recruiting
Not Applicable
Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinibMetastatic Renal Cell CarcinomaNCT06548867Gruppo Oncologico Italiano di Ricerca Clinica80
Recruiting
Not Applicable
Longitudinal Study of Local Ablative Therapy in Oligometastatic DiseaseOligometastatic DiseaseMetastasesAblation TechniquesRadiotherapyStereotactic RadiationSurgeryNCT06356779Gitte Fredberg Persson MD PhD1,200
Not yet recruiting
Not Applicable
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.Metastatic CancerNCT06363773Elsan35
Completed
Not Applicable
An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung CancerNCT01488331Hoffmann-La Roche217